Skip to main content

Share story

AI Capital

Altis Labs raises $25 million for oncology-trial AI

Altis Labs raised a $25 million Series A, CEO Felix Baldauf-Lenschen told Axios Pro. The AI software company analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, supporting a drug-development business built around trial imaging.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Techmeme and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Capital
AI Capital

Mithrl raises $20 million for biopharma AI infrastructure

Mithrl raised a $20 million Series A led by Obvious Ventures, CEO Vivek Adarsh told Axios. The company integrates its proprietary biomedical world model with pharmaceutical companies' research-and-development systems. The round gi...

AI Capital
AI Capital

Raindrop raises $35 million to monitor AI-agent failures

Raindrop raised a $35 million Series A led by CRV, co-founders Zubin Koticha and Ben Hylak told Axios Pro. The company builds technology to monitor AI agents for problems such as invented information and misuse of the tools they c...

Policy AI
Policy AI

OECD survey finds wider use of worker-sanction software in US firms

An OECD survey of 6,047 firms across six countries found 67% of US firms use software to sanction poor performance, versus 4% across France, Germany, Italy and Spain. It found US firms were also more likely to monitor conversation...